W. Shipley

W. Shipley, A. Althausen, G. Prout, 1993, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Ki-67 staining is a strong predictor of patient outcome for prostate cancer patients treated with androgen deprivation plus radiotherapy: an analysis of RTOG 92–02

H. Sandler, M. Desilvio, W. Shipley, 2003 .

Cisplatin and full dose irradiation for patients with invasive bladder carcinoma: a preliminary report of tolerance and local response.

A. Einstein, W. Shipley, M. Soloway, 1984, The Journal of urology.

Intraoperative irradiation: A pilot study combining external beam photons with “boost” dose intraoperative electrons

W. Shipley, W. Wood, P. Biggs, 1982, Cancer.

Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis.

A. Kishan, R. Mehra, H. Sandler, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial.

Charles R. Thomas, D. Grignon, M. Roach, 2006, International journal of radiation oncology, biology, physics.

Radiotherapy for bladder cancer.

Karin Haustermans, Farhat Abbas, Claus Rödel, 2007, Urology.

Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy.

W. Shipley, C. Fung, R. Young, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Invasive bladder carcinoma. The importance of initial transurethral surgery and other significant prognostic factors for improved survival with full‐dose irradiation

W. Shipley, G. Prout, T. Perrone, 1987, Cancer.

Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder.

A. Zietman, W. Shipley, R. Young, 2001, Urology.

Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of radiation therapy oncology group 89-03.

B. Donnelly, W. Shipley, C. Perez, 1998, The Journal of urology.

Full-dose irradiation for patients with invasive bladder carcinoma: clinical and histological factors prognostic of improved survival.

W. Shipley, G. Prout, N. Heney, 1985, The Journal of urology.

Bladder-sparing approaches to invasive disease

A. Zietman, J. Efstathiou, W. Shipley, 2006, World Journal of Urology.

Overview of bladder cancer trials in the Radiation Therapy Oncology Group

H. Sandler, W. Shipley, W. Tester, 2003, Cancer.

The durability of PSA failure-free survival from 5 years to 13 years following radiotherapy in patients with localized prostate cancer

A. Zietman, W. Shipley, T. Yock, 2000 .

Bladder cancer.Advances in laboratory innovations and clinical management, with emphasis on innovations allowing bladder‐sparing approaches for patients with invasive tumors

W. Shipley, G. Prout, D. Kaufman, 1990, Cancer.

Biology and management of bladder cancer.

J. Richie, W. Shipley, P. Russell, 1990, The New England journal of medicine.

Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer.

A. Zietman, W. Shipley, A. Althausen, 1997, International journal of radiation oncology, biology, physics.

Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.

Christopher U. Jones, H. Sandler, J. Efstathiou, 2016, European urology.

Cardiovascular mortality following short-term androgen deprivation in clinically localized prostate cancer: An analysis of RTOG 94-08.

Christopher U. Jones, H. Sandler, J. Efstathiou, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant radiation therapy for early stage seminoma: proton versus photon planning comparison and modeling of second cancer risk.

A. Niemierko, A. Zietman, J. Efstathiou, 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Mapping patterns of nodal metastases in seminoma: rethinking radiotherapy fields.

M. Harisinghani, A. Zietman, J. Efstathiou, 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Testicular seminoma: clinical and pathological features that may predict para-aortic lymph node metastases.

L. Marks, W. Shipley, T. Walker, 1990, The Journal of urology.

Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: experimental and clinical results.

A. Zietman, W. Shipley, E. Prince, 1997, Urology.

The role of misonidazole combined with intraoperative radiation therapy in the treatment of pancreatic carcinoma.

J. Tepper, W. Shipley, W. Wood, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trial.

Ronald C. Chen, A. Trofimov, K. Hoffman, 2010, International journal of radiation oncology, biology, physics.

The opportunity cost of androgen suppression in locally advanced prostate cancer.

P. Gray, J. Efstathiou, W. Shipley, 2013, Asian journal of andrology.

Radical prostatectomy and radical radiation therapy for clinical stages T1 to 2 adenocarcinoma of the prostate: new insights into outcome from repeat biopsy and prostate specific antigen followup.

A. Zietman, W. Shipley, J. Coen, 1994, The Journal of urology.

Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer.

J. Efstathiou, W. Shipley, W. Mcdougal, 2012, The Journal of urology.

Radiation therapy of Hodgkin's disease: Significance of splenic involvement

W. Shipley, S. Hellman, A. Piro, 1974, Cancer.

Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601

A. Zietman, H. Sandler, R. Dess, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Complications of intraoperative radiation therapy.

J. Tepper, W. Shipley, P. Blitzer, 1984, International journal of radiation oncology, biology, physics.

Bladder preservation in muscle-invasive bladder cancer by conservative surgery and radiochemotherapy.

A. Zietman, W. Shipley, J. Dunst, 2001, Seminars in surgical oncology.

Progress in the management of T3-4 adenocarcinoma of the prostate.

A. Zietman, W. Shipley, 1997, European journal of cancer.

Benchmarks achieved in the delivery of radiation therapy for muscle-invasive bladder cancer.

A. Zietman, W. Shipley, J. Coen, 2007, Urologic oncology.

[Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials].

D. Grignon, W. Shipley, J. Cox, 2001 .

Quality control parameters of intraoperative radiation therapy.

J. K. Martin, J. Tepper, W. Shipley, 1986, International journal of radiation oncology, biology, physics.

Integrating chemotherapy and radiotherapy for bladder cancer

J. Efstathiou, N. James, W. Shipley, 2015 .

Bladder cancer. Clinical practice guidelines in oncology.

J. Richie, P. Lange, J. Montie, 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

An organ-preserving approach to muscle-invading transitional cell cancer of the bladder.

A. Zietman, W. Shipley, A. L. Brown, 2001, Hematology/oncology clinics of North America.

The role of neoadjuvant or adjuvant chemotherapy for invasive bladder cancer Is there a benefit for survival or preserving the bladder?

W. Shipley, N. Miyanaga, S. Kamidono, 1998, Urologic oncology.

Treatment strategies using transurethral surgery, chemotherapy, and radiation therapy with selection that safely allows bladder conservation for invasive bladder cancer.

A. Zietman, W. Shipley, A. Althausen, 1997, Seminars in surgical oncology.

Bladder preservation by combined modality therapy for invasive bladder cancer.

A. Zietman, W. Shipley, L. Kachnic, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

THE STATUS OF BLADDER‐PRESERVING THERAPEUTIC STRATEGIES IN THE MANAGEMENT OF PATIENTS WITH MUSCLE‐INVASIVE BLADDER CANCER

H. Poppel, W. Shipley, L. Baert, 1995, International journal of urology : official journal of the Japanese Urological Association.

Selective bladder preservation by combination treatment of invasive bladder cancer.

W. Shipley, A. Althausen, N. Heney, 1993, The New England journal of medicine.

The combination of cis-platin based chemotherapy and radiation in the treatment of muscle-invading transitional cell cancer of the bladder.

A. Zietman, W. Shipley, D. Kaufman, 1993, International journal of radiation oncology, biology, physics.

Radiation as adjunctive therapy to cystectomy for bladder cancer.

W. Shipley, 1993, International journal of radiation oncology, biology, physics.

PSA Bounces After Neoadjuvant Androgen Deprivation and External Beam Radiation: Impact on Definitions of Failure

A. Zietman, W. Shipley, J. Christodouleas, 2006 .

PSA bounces after neoadjuvant androgen deprivation and external beam radiation: impact on definitions of failure.

A. Zietman, W. Shipley, J. Christodouleas, 2005, International journal of radiation oncology, biology, physics.

Invasive bladder carcinoma: preliminary report of selective bladder conservation by transurethral surgery, upfront MCV (methotrexate, cisplatin, and vinblastine) chemotherapy and pelvic irradiation plus cisplatin.

L. Marks, W. Shipley, G. Prout, 1988, International journal of radiation oncology, biology, physics.

Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery.

A. Einstein, W. Shipley, M. Hafermann, 1987, JAMA.

Bladder cancer. The selection of patients for treatment by full‐dose irradiation

W. Shipley, M. Rose, William U. Shipley, 1985 .

4,000 RAD preoperative irradiation followed by prompt radical cystectomy for invasive bladder carcinoma: a prospective study of patient tolerance and pathologic downstaging.

A. Einstein, W. Shipley, K. Cummings, 1982, The Journal of urology.

Potential location of a bladder tumor suppressor gene on chromosome 9q at 9q13 to 9q22.1.

D. Kwiatkowski, W. Shipley, D. Yandell, 1995, Urologic oncology.

Bladder preservation: optimizing radiotherapy and integrated treatment strategies

R. Mak, A. Zietman, W. Shipley, 2008, BJU international.

Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates--the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences.

A. Zietman, H. Sandler, W. Shipley, 2005, Seminars in radiation oncology.

Pure seminoma of the testis: the results of radiation therapy in patients with elevated human chorionic gonadotropin titers.

W. Shipley, J. Meyer, D. Dosoretz, 1985, The Journal of urology.

Invasive bladder cancer: treatment strategies using transurethral surgery, chemotherapy and radiation therapy with selection for bladder conservation.

A. Zietman, W. Shipley, A. Althausen, 1997, International journal of radiation oncology, biology, physics.

Cisplatin as adjunctive treatment for invasive bladder carcinoma: tolerance and toxicities.

A. Einstein, W. Shipley, M. Soloway, 1984, Urology.

A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer.

A. Zietman, W. Shipley, A. Althausen, 1998, The Journal of urology.

A PHASE MI TRIAL OF TRANSURETHRAL SURGERY COMBINED WITH RADIATION FOLLOWED BY SELECTIVE BLADDER PRESERVATION IN OPERABLE PATIENTS WITH MUSCLE INVADING BLADDER CANCER CONCURRENT CISPLATIN, 5-FLUOROURACIL AND TWICE DAILY

A. Zietman, W. Shipley, A. Althausen, 1998 .

Opportunities with combined modality therapy for selective organ preservation in muscle‐invasive bladder cancer

A. Zietman, W. Shipley, A. Althausen, 1996, Journal of surgical oncology.

Interval report of a phase I-II study utilizing multiple modalities in the treatment of invasive bladder cancer. A bladder-sparing trial.

W. Shipley, G. Prout, N. Heney, 1991, The Urologic clinics of North America.

Preliminary results in invasive bladder cancer with transurethral resection, neoadjuvant chemotherapy and combined pelvic irradiation plus cisplatin chemotherapy.

W. Shipley, A. Althausen, G. Prout, 1990, The Journal of urology.

Review of factors predicting improved tumor control and survival from invasive bladder carcinoma following external beam radiation therapy.

W. Shipley, 1988, Progress in clinical and biological research.

A Phase 1/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Noncystectomy Candidates With Muscle-Invasive Bladder Cancer (Trial NRG Oncology RTOG 0524).

M. Michaelson, H. Sandler, G. Swanson, 2017, International journal of radiation oncology, biology, physics.

L. True, B. Donnelly, W. Shipley, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trimodality therapy in the management of muscle-invasive bladder cancer: a selective organ-preserving approach

A. Zietman, W. Shipley, A. Althausen, 2008 .

An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy.

A. Zietman, W. Shipley, A. Althausen, 1999, The Journal of urology.

Megavoltage irradiation for pure testicular seminoma: Results and patterns of failure

W. Shipley, J. Prat, P. Blitzer, 1981, Cancer.

Influence of tumour size on hypoxic fraction and therapeutic sensitivity of Lewis lung tumour.

W. Shipley, G. Steel, J. Stanley, 1977, British Journal of Cancer.

The long-term effect on PSA values of incidental prostatic irradiation in patients with pelvic malignancies other than prostate cancer.

A. Zietman, W. Shipley, E. Zehr, 1999, International journal of radiation oncology, biology, physics.

Chapter 52 – Bladder Cancer

A. Zietman, J. Efstathiou, W. Shipley, 2012 .

Trimodality Therapy for Bladder Conservation in Treatment of Invasive Bladder Cancer

A. Zietman, J. Efstathiou, W. Shipley, 2013, Current Urology Reports.

Radiation therapy.

W. Shipley, 1992, The Journal of urology.

Thymosin beta-15 predicts for distant failure in patients with clinically localized prostate cancer-results from a pilot study.

A. Zietman, D. Finkelstein, W. Shipley, 2000, Urology.

Adriamycin sensitivity following "ultra" low dose rate irradiation of Lewis lung carcinoma in vivo.

W. Shipley, J. Peacock, G. Steel, 1985, International journal of radiation oncology, biology, physics.

Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer.

A. Zietman, W. Shipley, M. Katz, 2006, Urology.

Tumor size dependency in the radiation response of the Lewis lung carcinoma.

W. Shipley, G. Steel, J. Stanley, 1975, Cancer research.

A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521).

R. Hannan, J. Purdy, M. Amin, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intraoperative irradiation for unresectable pancreatic carcinoma

W. Shipley, W. Wood, A. Cohen, 1982, Cancer.

Two Years of Anti-Androgen Treatment Increases Other-Cause Mortality in Men Receiving Early Salvage Radiotherapy: A Secondary Analysis of the NRG Oncology/RTOG 9601 Randomized Phase III Trial

A. Zietman, H. Sandler, R. Dess, 2019, International Journal of Radiation Oncology*Biology*Physics.

Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease.

A. Zietman, W. Shipley, N. Heney, 1996, Urology.

Intraoperative irradiation: A pilot study combining external beam with “boost” dose intraoperative electrons

W. Shipley, W. Wood, P. Biggs, 1979 .

Androgen deprivation and radiation therapy in prostate cancer: the evolving case for combination therapy.

A. Zietman, W. Shipley, 1997, International journal of radiation oncology, biology, physics.

Old drugs, new purpose--bladder cancer turning a corner.

A. Zietman, W. Shipley, 2012, The New England journal of medicine.

Recent advances and the emerging role for chemoradiation in nonmuscle invasive bladder cancer

A. Zietman, P. Gray, J. Efstathiou, 2013, Current opinion in urology.

A Prospective Phase I/II Study using Proton Beam Radiation to Deliver 82GyE to Men with Localized Prostate Cancer: Preliminary Results of ACR 0312

A. Zietman, K. Bae, W. Shipley, 2008 .

Intraoperative Electron Beam Irradiation for Patients with Unresectable Pancreatic Carcinoma

J. Tepper, W. Shipley, W. Wood, 1981, Annals of Surgery.

Iodine‐125 implant and external beam irradiation in patients with localized pancreatic carcinoma. A comparative study to surgical resection

W. Shipley, A. Cohen, G. Nardi, 1980, Cancer.

The management of spermatic cord sarcoma

A. Zietman, W. Shipley, M. Fagundes, 1996, Cancer.

Deoxyribonucleic acid flow cytometry in invasive bladder carcinoma: a possible predictor for successful bladder preservation following transurethral surgery and chemotherapy-radiotherapy.

R. Colvin, S. Schwartz, W. Shipley, 1992, The Journal of urology.

Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.

A. Niemierko, M. Michaelson, A. Zietman, 2017, European urology.

Phase III trial of hormonal cytoreduction in conjunction with definitive radiotherapy in locally advanced prostate carcinoma: the emerging role of psa in the assessment of outcome

R. Abrams, P. Rubin, W. Sause, 1993 .

NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA.

D. Grignon, A. Zietman, H. Sandler, 2016 .

Contemporary Patterns of Multidisciplinary Care in Patients With Muscle‐invasive Bladder Cancer

K. Guru, A. Kiltie, B. Bochner, 2018, Clinical genitourinary cancer.

Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder

M. Michaelson, A. Zietman, W. Shipley, 2004, British Journal of Cancer.

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 3-2004. A 57-year-old man with invasive transitional-cell carcinoma of the bladder.

W. Shipley, W. Mcdougal, R. Young, 2004, The New England journal of medicine.

An Update of Selective Bladder Preservation by Combined Modality Therapy for Invasive Bladder Cancer

A. Zietman, W. Shipley, A. Althausen, 1998, European Urology.

Translational research in bladder cancer.

W. Shipley, 1996, International journal of radiation oncology, biology, physics.

1003 Chemotherapy and radiation therapy with selective organ-sparing treatment of invasive bladder cancer

W. Shipley, 1995 .

Organ-sparing treatment for bladder cancer: time to beat the drum.

A. Zietman, W. Shipley, 1994, International journal of radiation oncology, biology, physics.

Can chemo-radiotherapy plus transurethral tumor resection make cystectomy unnecessary for invasive bladder cancer?

W. Shipley, N. Heney, D. Kaufman, 1990, Oncology.

Analysis of MRE11 and Mortality Among Adults With Muscle-Invasive Bladder Cancer Managed With Trimodality Therapy

A. Zietman, F. Feng, P. Gray, 2022, JAMA network open.

RTOG 9706: initial report of a phase I/II trial of bladder-conservation employing TURB, accelerated irradiation sensitized with Cisplatin followed by adjuvant MCV chemotherapy

John D. Roberts, Christopher U. Jones, W. Shipley, 2001 .

Selective bladder preservation by combined modality treatment of invasive bladder cancer: 10-Year outcome

A. Zietman, W. Shipley, N. Heney, 2001 .

The biochemical and clinical significance of the post-treatment PSA bounce for prostate cancer patients treated with external beam radiation therapy alone: A multi-institutional pooled analysis

D. Kuban, M. Zelefsky, A. Zietman, 2004 .

The advantage of an X-ray visible marker of the prostatic apex.

W. Shipley, 1993, International journal of radiation oncology, biology, physics.

Spermatic cord sarcomas: Sonographic and CT features

W. Shipley, G. Cardenosa, C. Fung, 1990, Urologic radiology.

Conformal irradiation of the prostate: estimating long-term rectal bleeding risk using dose-volume histograms.

M M Urie, W. Shipley, M. Urie, 1996, International journal of radiation oncology, biology, physics.

Association of mammalian cell death with a specific endonucleolytic degradation of DNA

J. Little, W. Shipley, Jerry R. Williams, 1974, Nature.

Early prostate cancer: the national results of radiation treatment from the Patterns of Care and Radiation Therapy Oncology Group studies with prospects for improvement with conformal radiation and adjuvant androgen deprivation.

W. Shipley, T. Schultheiss, G. Hanks, 1994, The Journal of urology.

Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome.

A. Zietman, C. Willett, W. Shipley, 1994, The Journal of urology.

Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base.

A. Jemal, A. Kibel, M. Blute, 2014, International journal of radiation oncology, biology, physics.

The use of local allograft irradiation following renal transplantation.

W. Shipley, F. Delmonico, E. Halperin, 1984, International journal of radiation oncology, biology, physics.

Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases.

A. Gown, E. Oliva, M. Amin, 2013, Human pathology.

Penile cancer: Clinical Practice Guidelines in Oncology.

Geoffrey E. Wile, J. Richie, D. Kuban, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Response to continuous irradiation (CI) in relation to the initial slope of the cell survival curve for tumours and bone marrow.

W. Shipley, J. Peacock, G. Steel, 1984, The British journal of cancer. Supplement.

Repair of radiation damage in Lewis lung carcinoma cells following in situ treatment with fast neutrons and gamma-rays.

S. B. Field, V. Courtenay, W. Shipley, 1975, Cancer research.

Reduction of the scatter dose to the testicle outside the radiation treatment fields.

W. Shipley, H. Kubo, 1982, International journal of radiation oncology, biology, physics.

Radiation Therapy: its Integration with Surgery and Chemotherapy in the Management of Patients with Urological Malignancy

W. Shipley, 1989 .

Early stage testicular seminoma: the role of radiation therapy following orchiectomy.

A. Zietman, W. Shipley, B. Nakfoor, 1994, Frontiers of radiation therapy and oncology.

DNA damage and repair following irradiation: the effect of 5-bromodeoxyuridine in cultured Chinese hamster cells.

W. Shipley, M. Elkind, 1971, Radiation research.

Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison.

Alexei Trofimov, Paul L Nguyen, Anthony L Zietman, 2007, International journal of radiation oncology, biology, physics.

Treatment of malignant tumors of the spermatic cord: a study of 10 cases and a review of the literature.

W. Shipley, P. Blitzer, K. Proppe, 1981, The Journal of urology.

Role of lymphangiography in stagingtesticular seminoma

Thomas G. Walker, L. Marks, W. Shipley, 1991 .

Preoperative irradiation, lymphadenectomy, and 125iodine implantation for patients with localized carcinoma of the prostate.

W. Shipley, P. Biggs, T. Delaney, 1986, International journal of radiation oncology, biology, physics.

Potentiation of x-ray killing by 5-bromodeoxyuridine in Chinese hamster cells: a reduction in capacity for sublethal damage accumulation.

W. Shipley, W. Prather, M. Elkind, 1971, Radiation research.

Radiation Therapy for Clinically Localized Prostate Cancer

D. Kuban, S. Hancock, A. Zietman, 2016 .

Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis.

D. Kuban, S. Hancock, A. Zietman, 1999, JAMA.

Obesity and mortality in men with locally advanced prostate cancer

H. Sandler, K. Bae, J. Efstathiou, 2007, Cancer.

Management of carcinoma of the bladder.

Z. Petrovich, W. Shipley, L. Baert, 1998, American journal of clinical oncology.

Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.

M. Hammond, H. Sandler, M. Desilvio, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of a biopsy-based genomic classifier in high-risk prostate cancer: Meta-analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 phase III randomized trials.

H. Sandler, F. Feng, D. Spratt, 2022, International journal of radiation oncology, biology, physics.

Adenovirus‐mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo

Min Zhang, A. Zietman, W. Shipley, 2005, The Prostate.

Residual, unresectable, or recurrent colorectal cancer: external beam irradiation and intraoperative electron beam boost +/- resection.

W. Shipley, W. Wood, H. Suit, 1983, International journal of radiation oncology, biology, physics.

Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone.

L. Verhey, A. Zietman, M. Goitein, 1995, International journal of radiation oncology, biology, physics.

Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer

H. Sandler, P. Tran, F. Feng, 2021, JAMA oncology.

Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer.

W. R. Lee, A. Kishan, A. Zietman, 2020, JAMA oncology.

Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial.

R. Hannan, H. Sandler, J. Purdy, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer

D. Grignon, A. Zietman, H. Sandler, 2017, The New England journal of medicine.

Bladder cancer

W. Shipley, William U Shipley, D. Kaufman, 2009, The Lancet.

Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis.

D. Kuban, M. Zelefsky, A. Zietman, 2005, The Journal of urology.

The effect of pelvic radiation therapy on serum levels of prostate specific antigen.

A. Zietman, C. Willett, W. Shipley, 1994, The Journal of urology.

Renal complications secondary to radiation treatment of upper abdominal malignancies.

C. Willett, J. Tepper, W. Shipley, 1986, International journal of radiation oncology, biology, physics.

Intraoperative Electron Beam Irradiation for Patients with Unresectable Pancreatic Carcinoma

J. Tepper, W. Shipley, W. Wood, 1981, Annals of surgery.

COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial.

D. Grignon, M. Hammond, H. Sandler, 2007, The Lancet. Oncology.

Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer.

Ronald C. Chen, A. Niemierko, A. Zietman, 2015, International journal of radiation oncology, biology, physics.

Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors.

A. Zietman, W. Shipley, Jack Clark, 2003, The Journal of urology.

Clinical experience with proton beam radiation therapy.

L. Verhey, E. Gragoudas, M. Goitein, 1980, Journal of the Canadian Association of Radiologists.

Intraoperative radiation therapy for patients with pancreatic carcinoma

J. Tepper, W. Shipley, A. Warshaw, 1984, World Journal of Surgery.

Prognostic value of survivin in locally advanced prostate cancer: study based on RTOG 8610.

Min Zhang, H. Sandler, Yoshiyuki Suzuki, 2005, International journal of radiation oncology, biology, physics.

Laparoscopy in the staging and planning of therapy for pancreatic cancer.

J. Tepper, W. Shipley, A. Warshaw, 1986, American journal of surgery.

Survivin is a potential mediator of prostate cancer metastasis.

Min Zhang, A. Niemierko, A. Zietman, 2010, International journal of radiation oncology, biology, physics.

Nodal involvement as a prognostic indicator in patients with prostatic carcinoma.

W. Shipley, G. Prout, J. Daly, 1980, The Journal of urology.

Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.

M. Terris, A. Kishan, M. Cooperberg, 2019, JAMA oncology.

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

Paul Schellhammer, P. Schellhammer, H. Sandler, 2006, International journal of radiation oncology, biology, physics.

Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.

D. Grignon, W. Shipley, G. Hanks, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiation dose-volume effects of the urinary bladder.

Lawrence B Marks, Patricia J Eifel, Akila N Viswanathan, 2010, International journal of radiation oncology, biology, physics.

Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases.

A. Zietman, W. Shipley, J. Coen, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.

Christopher U. Jones, K. Pienta, D. Grignon, 2015, International journal of radiation oncology, biology, physics.

Long-term results of adjuvant versus early salvage postprostatectomy radiation: A large single-institutional experience.

A. Niemierko, A. Zietman, J. Efstathiou, 2017, Practical radiation oncology.

Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer.

F. Feng, J. Efstathiou, W. Shipley, 2018, The Lancet. Oncology.

The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome.

A. Zietman, W. Shipley, J. Coen, 1995, International journal of radiation oncology, biology, physics.

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

D. Grignon, T. Pajak, H. Sandler, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910.

H. Sandler, M. Amin, T. Pisansky, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiotherapy and short-term androgen deprivation for localized prostate cancer.

Christopher U. Jones, H. Sandler, M. Amin, 2011, The New England journal of medicine.

Conservative surgery, patient selection, and chemoradiation as organ-preserving treatment for muscle-invading bladder cancer.

A. Zietman, W. Shipley, A. Althausen, 1996, Seminars in oncology.

Bladder cancer.

Geoffrey E. Wile, J. Richie, D. Kuban, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.

A. Zietman, H. Sandler, R. Uzzo, 2014, International journal of radiation oncology, biology, physics.

Impact of biochemical failure classification on clinical outcome: A secondary analysis of Radiation Therapy Oncology Group 9202 and 9413

H. Sandler, K. Bae, W. Shipley, 2015, Cancer.

Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06.

H. Sandler, R. Valicenti, J. Michalski, 2011, International journal of radiation oncology, biology, physics.

Influence of follow-up bias on PSA failure after external beam radiotherapy for localized prostate cancer: results from a 10-year cohort analysis.

A. Zietman, W. Shipley, J. Coen, 2003, International journal of radiation oncology, biology, physics.

Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the Radiation Therapy Oncology Group protocol 86-10.

P. Okunieff, R. Abrams, W. Shipley, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610.

D. Grignon, R. Abrams, K. Fu, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610.

D. Grignon, R. Abrams, F. Sarkar, 1997, Journal of the National Cancer Institute.

Comparative Effectiveness of Bladder‐preserving Tri‐modality Therapy Versus Radical Cystectomy for Muscle‐invasive Bladder Cancer

P. Pandharipande, J. Efstathiou, W. Shipley, 2018, Clinical genitourinary cancer.

Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.

R. Mak, A. Zietman, J. Efstathiou, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ki-67 Staining Index Predicts Distant Metastasis and Survival in Locally Advanced Prostate Cancer Treated With Radiotherapy

D. Grignon, M. Hammond, H. Sandler, 2004, Clinical Cancer Research.

Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer.

Andrzej Niemierko, Jerry D. Slater, A. Niemierko, 2010, JAMA.

The integration of chemotherapy, radiotherapy and transurethral surgery in bladder-sparing approaches for patients with invasive tumors.

W. Shipley, A. Althausen, G. Prout, 1990, Progress in clinical and biological research.

Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum.

E. Petricoin, S. Groshen, F. Waldman, 2014, Urologic oncology.

Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.

A. Zietman, H. Sandler, J. Efstathiou, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trimodality bladder preservation therapy for muscle-invasive bladder cancer.

Ronald C. Chen, A. Zietman, J. Efstathiou, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response.

L. True, W. Sause, W. Shipley, 2000, The oncologist.

Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.

Nicholas D James, Wassim Kassouf, S. Shariat, 2014, European urology.

Muscle-invading bladder cancer, RTOG Protocol 99-06: Initial report of a phase I/II trial of selective bladder-conservation employing TURBT, accelerated irradiation sensitized with cisplatin and paclitaxel followed by adjuvant cisplatin and gemcitabine chemotherapy

H. Sandler, W. Shipley, A. Althausen, 2005 .

RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy.

John D. Roberts, Christopher U. Jones, A. Zietman, 2003, International journal of radiation oncology, biology, physics.

Current concepts in the management of patients with deeply invasive bladder carcinoma.

A. Einstein, W. Shipley, K. Cummings, 1979, Seminars in oncology.

Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base.

A. Zietman, P. Gray, J. Efstathiou, 2013, European urology.

Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06.

H. Sandler, K. Bae, J. Efstathiou, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radio-chemotherapy for invasive carcinoma of the bladder.

W. Shipley, A. Althausen, G. Prout, 1992, Frontiers of radiation therapy and oncology.

Bladder cancer. The selection of patients for treatment by full-dose irradiation.

W. Shipley, M. Rose, 1985, Cancer.

Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408.

Christopher U. Jones, J. Torres-Roca, H. Sandler, 2015, International journal of radiation oncology, biology, physics.

Dose inhomogeneity in interstitial implants using 125I seeds.

L. Anderson, C. Ling, W. Shipley, 1979, International journal of radiation oncology, biology, physics.

Proton radiation as boost therapy for localized prostatic carcinoma.

M Goitein, A M Koehler, L J Verhey, 1979, JAMA.

Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995.

D. Kuban, M. Zelefsky, A. Zietman, 2003, International journal of radiation oncology, biology, physics.

In response to Drs. Kataria Sethi, Negi, and Rawat

W. Shipley, 2003 .

Title: Bladder Preservation Therapy for Muscle-Invading Bladder Cancers on RTOG 8802, 8903, 9506, and 9706: Vascular endothelial growth factor B over expression predicts for increased distant metastasis and shorter survival

J. Efstathiou, W. Shipley, Chin-Lee Wu, 2013 .

Acute and late urinary toxicity following radiation in men with an intact prostate gland or after a radical prostatectomy: A secondary analysis of RTOG 94-08 and 96-01.

Christopher U. Jones, R. Mak, H. Sandler, 2016, Urologic oncology.

Continuous irradiation of the Lewis lung carcinoma in vivo at clinically-used "ultra" low-dose-rates.

W. Shipley, J. Peacock, G. Steel, 1983, International journal of radiation oncology, biology, physics.

Prostatectomy or watchful waiting in prostate cancer.

A. Zietman, W. Shipley, J. Coen, 2003, New England Journal of Medicine.

Inflammatory metastatic breast cancer with gallbladder metastasis: an incidental finding.

W. Shipley, H. Ebrahim, D. Rice, 2015, The Journal of community and supportive oncology.

Outcomes in a multi-institutional cohort of patients treated with intraoperative radiation therapy for advanced or recurrent renal cell carcinoma.

Andrzej Niemierko, Felipe A Calvo, Anthony L Zietman, 2012, International journal of radiation oncology, biology, physics.

Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.

D. Grignon, H. Sandler, K. Bae, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Late rectal bleeding following combined X-ray and proton high dose irradiation for patients with stages T3-T4 prostate carcinoma.

M Goitein, M M Urie, C. Willett, 1993, International journal of radiation oncology, biology, physics.

Carcinoma of the female urethra: a review of results with radiation therapy.

W. Shipley, S. Sailer, C. C. Wang, 1988, The Journal of urology.

A strategy against pancreatic cancer.

W. Shipley, P. Mueller, D. Podolsky, 1982, Journal of clinical gastroenterology.

The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995.

D. Kuban, M. Zelefsky, A. Zietman, 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate.

A. Zietman, W. Shipley, R. Zlotecki, 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.

H. Sandler, R. Valicenti, M. Desilvio, 2006, International journal of radiation oncology, biology, physics.

Defining recurrence after radiation for prostate cancer.

D. Kuban, H. Thames, W. Shipley, 2005, The Journal of urology.

Definitions of biochemical failure that best predict clinical failure in prostate cancer patients treated with external beam radiation alone- a multi-institutional pooled analysis

D. Kuban, M. Zelefsky, A. Zietman, 2003 .

Biochemical and clinical significance of the posttreatment prostate‐specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone

D. Kuban, M. Zelefsky, A. Zietman, 2006, Cancer.

Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706.

P. Rubin, S. Doggett, W. Sause, 1991, International journal of radiation oncology, biology, physics.

Protons or megavoltage X‐rays as boost therapy for patients irradiated for localized prostatic carcinoma an early phase I/II comparison

L. Verhey, M. Goitein, W. Shipley, 1983, Cancer.

Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II study 03-12.

Kyounghwa Bae, Jerry D. Slater, A. Zietman, 2011, International journal of radiation oncology, biology, physics.

Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: analysis of efficacy and prognostic factors.

A. Zietman, W. Shipley, H. Thakral, 2002, Urology.

Hormonal therapies: ADT for prostate cancer: true love or heartbreak?

A. Zietman, J. Efstathiou, W. Shipley, 2010, Nature Reviews Clinical Oncology.

Radiotherapy and chemotherapy in invasive bladder cancer with potential bladder sparing.

W. Shipley, A. Althausen, D. Kaufman, 1992, Hematology/oncology clinics of North America.

Adding short-term androgen deprivation therapy to RT in men with localized prostate cancer: long-term update of the NRG/RTOG 9408 randomized clinical trial.

Christopher U. Jones, A. Zietman, H. Sandler, 2021, International journal of radiation oncology, biology, physics.

Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.

H. Sandler, K. Bae, J. Efstathiou, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.

H. Sandler, K. Bae, J. Efstathiou, 2008, European urology.

Outcomes of Selective Bladder Preservation in the Elderly Treated With Conservative Surgery and Chemoradiation

A. Niemierko, A. Zietman, P. Gray, 2013 .

Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial.

A. Zietman, H. Sandler, R. Uzzo, 2013, The Lancet. Oncology.

Clinical-pathologic stage discrepancy in patients with bladder cancer treated with radical cystectomy: Associations with clinical variables and survival.

A. Jemal, A. Kibel, A. Zietman, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The results of concurrent chemo‐radiotherapy for recurrence after treatment with bacillus Calmette‐Guérin for non‐muscle‐invasive bladder cancer: is immediate cystectomy always necessary?

A. Zietman, W. Shipley, N. Heney, 2009, BJU international.

Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.

A. Zietman, H. Sandler, W. Shipley, 2009, Urology.

Multi-institutional matched comparison of radical cystectomy to trimodality therapy for muscle-invasive bladder cancer.

A. Niemierko, R. Bristow, A. Zietman, 2022, Journal of Clinical Oncology.

Incidence, Clinicopathological Risk Factors, Management and Outcomes of Nonmuscle Invasive Recurrence after Complete Response to Trimodality Therapy for Muscle Invasive Bladder Cancer

A. Niemierko, A. Zietman, J. Efstathiou, 2018, The Journal of urology.

Bladder cancer. Clinical guidelines in oncology.

J. Richie, P. Lange, J. Montie, 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

Celebrating 40 years of clinical inquiry: The RTOG'S ruby anniversary.

W. Curran, W. Shipley, T. Wasserman, 2008, International journal of radiation oncology, biology, physics.

The demonstration in the domestic guinea pig of a process resembling classical imprinting

W. Shipley, 1963 .

RADIATION THERAPY ONCOLOGY GROUP RTOG 0926 A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1 BLADDER CANCER TO EVALUATE SELECTIVE BLADDER PRESERVING TREATMENT BY RADIATION THERAPY CONCURRENT WITH RADIOSENSITIZING CHEMOTHERAPY FOLLOWING A THOROUGH TRANSURETHRAL SURGICAL RE-STAGING

M. Michaelson, W. Shipley, Chin-Lee Wu, 2012 .

Radiation-sensitizing chemotherapy after transurethral resection as an alternative treatment for high-risk T1 bladder cancer

W. Shipley, 2007, Nature Clinical Practice Urology.

Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer.

Andrzej Niemierko, Anthony L Zietman, A. Niemierko, 2013, International journal of radiation oncology, biology, physics.

Combined modality treatment with selective bladder conservation for invasive bladder cancer: long-term tolerance in the female patient.

A. Zietman, W. Shipley, L. Kachnic, 1996, The cancer journal from Scientific American.

Organ-conserving approaches to muscle-invasive bladder cancer: future alternatives to radical cystectomy

A. Zietman, W. Shipley, D. Kaufman, 2000, Annals of medicine.

Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.

F. Feng, E. Davicioni, J. Efstathiou, 2019, European urology.

Selective Bladder Preservation with Twice-Daily Radiation Plus 5-Flourouracil/Cisplatin or Daily Radiation Plus Gemcitabine for Patients with Muscle Invasive Bladder Cancer—Primary Results of NRG/RTOG 0712: A Randomized Phase 2 Multicenter Trial

A. Zietman, H. Sandler, J. Efstathiou, 2017 .

Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202.

D. Grignon, Min Zhang, H. Sandler, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical characteristics and outcomes of nonurothelial cell carcinoma of the bladder: Results from the National Cancer Data Base.

A. Jemal, P. Gray, J. Efstathiou, 2017, Urologic oncology.

42 A phase trial of transurethral surgery plus cisplatin and radiation therapy followed by either selective bladder preservation or radical cystectomy for patients with muscle-invading bladder cancer but without hydronephrosis

A. Zietman, W. Shipley, A. Althausen, 1997 .

Complications and Outcomes of Salvage Cystectomy after Trimodality Therapy

M. Blute, J. Efstathiou, W. Shipley, 2021, The Journal of urology.

Bladder preservation strategies.

J. Efstathiou, W. Shipley, A. Jani, 2015, Hematology/oncology clinics of North America.

Re: Radiotherapy With or Without Chemotherapy in Muscle-Invasive Bladder Cancer

J. Efstathiou, W. Shipley, D. Wood, 2012 .

Optimizing full-dose radiation therapy in the successful bladder-sparing management of patients with invasive bladder carcinoma

W. Shipley, 1988, World Journal of Urology.

Cisplatin and external beam radiation in patients with invasive bladder cancer.

W. Shipley, 1989, International journal of radiation oncology, biology, physics.

The role of radiation therapy and chemotherapy in the treatment of invasive carcinoma of the urinary bladder.

W. Shipley, G. Prout, S. Kaufman, 1988, Seminars in oncology.

Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10.

P. Rubin, W. Sause, W. Shipley, 2002, International journal of radiation oncology, biology, physics.

PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.

D. Kuban, M. Zelefsky, A. Zietman, 2004, International journal of radiation oncology, biology, physics.

Preoperative irradiation, lymphadenectomy and 125iodine implant for patients with localized prostatic carcinoma: a correlation of implant dosimetry with clinical results.

C. Ling, W. Shipley, G. Prout, 1980, The Journal of urology.

Radiation therapy for testicular seminoma: controversies in the management of early-stage disease.

M. Anscher, L. Marks, W. Shipley, 1992, Oncology.

Bcl-2 and Bax Expression Predict Prostate Cancer Outcome in Men Treated with Androgen Deprivation and Radiotherapy on Radiation Therapy Oncology Group Protocol 92-02

H. Sandler, M. Ritter, W. Shipley, 2007, Clinical Cancer Research.

Short-term Endocrine Therapy Prior to and during Radiation Therapy Improves Overall Survival in Patients with T1b-T2b Adenocarcinoma of the Prostate and PSA ≤ 20: Initial Results of RTOG 94-08

Christopher U. Jones, H. Sandler, M. Amin, 2010 .

Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02.

W. Shipley, G. Hanks, C. Lawton, 2008, International journal of radiation oncology, biology, physics.

Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10.

P. Rubin, M. Desilvio, W. Sause, 2006, International journal of radiation oncology, biology, physics.

Long-term outcomes in patients with muscle-invasive bladder cancer after bladder-preserving combined-modality therapy: A pooled analysis of RTOG 8802, 8903, 9506, 9706, 9906, and 0233.

R. Mak, A. Zietman, J. Efstathiou, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Surgery: Selective bladder-preserving therapy for muscle-invasive cancer

W. Shipley, N. Heney, D. Kaufman, 2009, Nature Reviews Clinical Oncology.

Reduction of the Scatter Dose to the Testicle Outside the Radiation Treatment Fields

W. Shipley, H. Kubo, 1983 .

Radiation therapy for localized prostate carcinoma: experience at the Massachusetts General Hospital (1973-1981).

W. Shipley, A. Althausen, G. Prout, 1988, NCI monographs : a publication of the National Cancer Institute.

A randomized trial comparing conventional dose (70.2GyE) and high-dose (79.2GyE) conformal radiation in early stage adenocarcinoma of the prostate: Results of an interim analysis of PROG 95–09

Judy Adams, B. Berkey, Jerry D. Slater, 2004 .

Bladder preservation therapy for muscle-invading bladder cancers on Radiation Therapy Oncology Group trials 8802, 8903, 9506, and 9706: vascular endothelial growth factor B overexpression predicts for increased distant metastasis and shorter survival.

H. Sandler, J. Efstathiou, W. Shipley, 2013, The oncologist.

Urological cancer: The benefits of intermittent androgen-deprivation therapy

J. Efstathiou, W. Shipley, T. Mitin, 2012, Nature Reviews Clinical Oncology.

Long-term outcomes in patients with muscle-invasive bladder cancer after bladder-preserving combined-modality therapy: A pooled analysis of RTOG 8802, 8903, 9506, 9706, 9906, and 0233.

R. Mak, A. Zietman, J. Efstathiou, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Flow cytometric analysis of DNA ploidy, percent S-phase fraction, and total proliferative fraction as prognostic indicators of local control and survival following radiation therapy for prostate carcinoma.

A. Zietman, R. Colvin, W. Shipley, 1994, International journal of radiation oncology, biology, physics.

The Importance of Protein Kinase A in Prostate Cancer: Relationship to Patient Outcome in Radiation Therapy Oncology Group Trial 92-02

M. Hammond, H. Sandler, K. Bae, 2009, Clinical Cancer Research.

Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups.

D. Kuban, M. Zelefsky, A. Zietman, 2006, International Journal of Radiation Oncology, Biology, Physics.

Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all?

D. Kuban, M. Zelefsky, A. Zietman, 2003, International journal of radiation oncology, biology, physics.

Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy.

R. Weissleder, M. Harisinghani, A. Zietman, 2009, Clinical imaging.

NCCN Urothelial Cancer Practice Guidelines

James M. Kozlowski, Jerome P. Richie, Howard I. Scher, 1998 .

NCCN urothelial cancer practice guidelines. National Comprehensive Cancer Network.

A Pollack, W Shipley, J. Richie, 1998, Oncology.

Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trial.

D. Grignon, B. Fisher, H. Sandler, 2007, International journal of radiation oncology, biology, physics.

Residual disease after radical surgery or radiation therapy for prostate cancer. Clinical significance and therapeutic implications

A. Zietman, C. Willett, W. Shipley, 1993, Cancer.

Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: a case-matched analysis.

A. Zietman, J. Efstathiou, W. Shipley, 2012, International journal of radiation oncology, biology, physics.

Preliminary Results of RTOG 0233: A Phase II Randomized Trial for Muscle-invading Bladder Cancer Treated by Transurethral Resection and Radiotherapy Comparing Two Forms of Concurrent Induction Chemotherapy

A. Zietman, H. Sandler, R. Uzzo, 2010 .

Full-dose irradiation for invasive bladder cancer: prognostic factors and techniques.

W. Shipley, 1984, Urology.

Adjuvant irradiation after radical prostatectomy for adenocarcinoma of prostate: analysis of freedom from PSA failure.

A. Zietman, W. Shipley, A. Althausen, 1993, Urology.

Organ conservation as an alternative to radical cystectomy for invasive bladder cancer: urodynamic and quality of life evaluation of patients treated by trimodality therapy

A. Zietman, W. Shipley, A. Althausen, 2002 .

Future prospects of radiation therapy with protons.

L. Verhey, W. Shipley, J. Munzenrider, 1981, Seminars in oncology.

Editorial: Radical Treatment With Radiation of “Early Stage” Prostate Cancer: Impressive Results With Long-Term Followup

W. Shipley, 1994 .

Reply from Authors re: Giuseppe Simone, Michele Gallucci. Multimodality Treatment Versus Radical Cystectomy: Bladder Sparing at Cost of Life? Eur Urol 2012;61:712–3: Bladder-Sparing Therapy: The Urologist Doth Protest Too Much, Methinks

A. Zietman, J. Efstathiou, W. Shipley, 2012 .

The importance of combined radiation and endocrine therapy in locally advanced prostate cancer.

P. Gray, W. Shipley, 2012, Asian journal of andrology.

The value of CT scanning in radiation therapy treatment planning: a prospective study.

M Goitein, H V Fineberg, H. Fineberg, 1979, International journal of radiation oncology, biology, physics.

Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial.

H. Sandler, K. Bae, W. Shipley, 2009, Journal of the National Cancer Institute.

Patient‐reported outcomes after 3‐dimensional conformal, intensity‐modulated, or proton beam radiotherapy for localized prostate cancer

A. Zietman, H. Sandler, B. Yeap, 2013, Cancer.

Intraoperative radiation therapy in patients with bladder cancer. A review of techniques allowing improved tumor doses and providing high cure rates without loss of bladder function

W. Shipley, S. Kaufman, G. Prout, 1987, Cancer.

Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation.

M. Michaelson, A. Zietman, H. Sandler, 2023, European urology oncology.

The success of radiation therapy in controlling prostatic cancer within the treated field.

W. Shipley, G. Prout, M. Bagshaw, 1987, Progress in clinical and biological research.

The Long-Term Success of Local Radiation Therapy in Preventing Tumor Regrowth in the Treated Field

W. Shipley, A. Althausen, G. Prout, 1988 .

Long-term Outcomes After Bladder-Preserving Combined Modality Therapy for Patients With Muscle-Invasive Bladder Cancer

A. Niemierko, M. Michaelson, A. Zietman, 2015 .

Management of spinal cord compression secondary to metastatic prostatic carcinoma.

W. Shipley, D. Flynn, 1991, The Urologic clinics of North America.

Report of NRG Oncology/RTOG 9601, A Phase 3 Trial in Prostate Cancer: Anti-androgen Therapy (AAT) With Bicalutamide During and After Radiation Therapy (RT) in Patients Following Radical Prostatectomy (RP) With pT2-3pN0 Disease and an Elevated PSA

D. Grignon, A. Zietman, H. Sandler, 2016 .

10-year outcome for men with localized prostate cancer treated with external radiation therapy: results of a cohort study.

A. Zietman, W. Shipley, J. Coen, 2004, The Journal of urology.

Enhanced tumor cell radiosensitivity in artificial pulmonary metastases of the Lewis lung carcinoma.

W. Shipley, G. Steel, J. Stanley, 1976, International journal of radiation oncology, biology, physics.

A three-dimensional ct based analysis of inter-fraction bladder motion during radiotherapeutic treatment of bladder cancer

A. Zietman, W. Shipley, A. Mazal, 2004 .

308: An Update of Selective Bladder Preservation Using Combined Modality Treatment in Invasive Bladder Cancer: Long Term Outcome Reveals a Low Risk of Invasive Recurrence and a High Probability of Bladder Preservation

A. Zietman, W. Shipley, A. Althausen, 2004 .

Receipt of aggressive therapies for muscle-invasive bladder cancer: Results from the National Cancer Data Base.

A. Zietman, P. Gray, J. Efstathiou, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nodal involvement as prognostic indicator in prostatic carcinoma.

W. Shipley, G. Prout, J. Daly, 1981, Urology.

Intraoperative radiation therapy.

J. Tepper, W. Shipley, W. Wood, 1985, Important advances in oncology.

Prolonged "ultra" low-dose-rate irradiation: effects on Chinese hamster cell population growth, survival, and radiation sensitivity.

C. Ling, W. Shipley, L. Gerweck, 1981, Radiation Research.

Randomized Trials in Loco-Regionally Confined Prostate Cancer: Past, Present, and Future.

Shipley, A. Zietman, W. Shipley, 1993, Seminars in radiation oncology.

Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy.

W. Curran, C. Gwede, K. Fu, 2000, International journal of radiation oncology, biology, physics.

Cardiovascular mortality following short-term androgen deprivation in clinically localized prostate cancer: An analysis of RTOG 94-08.

Christopher U. Jones, H. Sandler, J. Efstathiou, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

VIV0 AT CLINICALLY-USED "ULTRA" LOW-DOSE-RATES

W. Shipley, J. Peacock, G. Steel, 1983 .

Preoperative radiation, lymphadenectomy and iodine-125 implant for selected patients with localized prostatic carcinoma: A correlation of implant dosimetry with clinical results

C. Ling, W. Shipley, G. Prout, 1979 .

Long-term outcome for men with prostate cancer treated with radiation as solo therapy

A. Zietman, W. Shipley, A. Althausen, 1994 .

Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base.

A. Zietman, P. Gray, J. Efstathiou, 2013, European urology.

DNA degradation in mammalian cells following complement-mediated cytolysis.

H. Colten, W. Shipley, A. R. Baker, 1971, Journal of immunology.

Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis.

D. Kuban, S. Hancock, A. Zietman, 1999, JAMA.

Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.

H. Sandler, K. Bae, J. Efstathiou, 2008, European urology.

The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995.

D. Kuban, M. Zelefsky, A. Zietman, 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Re: Radiotherapy with or without Chemotherapy in Muscle-invasive Bladder Cancer

J. Efstathiou, W. Shipley, 2013 .

DRIAMYGIN SENSITIVITY FOLLOWING "ULTRA" LOW TE IRRADIATION OF LEWIS LUNG CARCINOMA IN

W. Shipley, G. Steel, T. Stephens, 1985 .

Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.

S. Shariat, C. Sternberg, J. Efstathiou, 2014, European urology.

Adjuvant radiation therapy for early stage seminoma: proton versus photon planning comparison and modeling of second cancer risk.

A. Niemierko, A. Zietman, J. Efstathiou, 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Penile cancer: Clinical Practice Guidelines in Oncology.

Geoffrey E. Wile, J. Richie, D. Kuban, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Does neoadjuvant hormone treatment compromise subsequent androgen suppression in prostate cancer patients who fail initial radiation therapy: a secondary analysis of RTOG 86-10

P. Rubin, W. Sause, W. Shipley, 2000 .

Immune cytolysis and x irradiation: independent lethal action in Chinese hamster cells in vitro.

W. Shipley, 1972, Journal of the National Cancer Institute.

Re: Radical Cystectomy vs. Chemoradiation in T2-4aN0M0 Bladder Cancer: A Case-control Study

P. Gray, J. Efstathiou, W. Shipley, 2016 .

Adjuvant radiation therapy for pathologic T3 prostate cancer

A. Zietman, W. Shipley, A. Althausen, 1993 .

Proton Beam Therapy in Localized Prostate Cancer

A. Zietman, W. Shipley, 2000 .